Beta Bionics, Inc. Common Stock (BBNX) — Cash Flow-to-Debt Ratio
Beta Bionics, Inc. Common Stock (BBNX) has a Cash Flow-to-Debt Ratio of -0.72x as of March 2026, meaning its operating cash flow of $-23.83 Million could theoretically repay -1% of its total liabilities ($33.17 Million) in one year. Explore Beta Bionics, Inc. Common Stock (BBNX) long-term investment share to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Beta Bionics, Inc. Common Stock Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for Beta Bionics, Inc. Common Stock across 4 annual periods. Also explore BBNX total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Beta Bionics, Inc. Common Stock (2022–2025)
Year-by-year debt coverage analysis for Beta Bionics, Inc. Common Stock. For market capitalisation and broader financial context, see BBNX company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.24x | $-50.92 Million | $41.13 Million | ▼ -88.8% |
| 2024 | -0.66x | $-48.27 Million | $73.63 Million | ▼ -3.9% |
| 2023 | -0.63x | $-32.45 Million | $51.43 Million | ▲ +76.4% |
| 2022 | -2.67x | $-60.21 Million | $22.53 Million | — |